Sophia Mowla

Principal

Sophia specialises in placing global C-Suite and Board level executives in Digital Healthcare, Pharmaceutical, Biotechnology, Medical Device & Diagnostics industries. She has a track record in venture capital & private equity. During her PhD, she opened her own consultancy advising funds on pre-deal due-diligence and business development.

Prior to True, Sophia was a key member of the Global Healthcare practice at Russell Reynolds Associates. She has a deep passion for transformational technology; she has placed CEOs/Executive Chairs for a number of VC & PE backed companies that have since gone through successful exit. Her portfolio includes devising the board for a healthcare company pre-IPO, which then listed on the FTSE 100.

Sophia is a published scientist, she holds a First Class Master’s degree from University College London in Natural Sciences, specializing in Cell & Molecular Biology and Science Communication. She was nominated for the European Science Engineering and Technology awards for her discovery of novel anti-cancer and anti-ageing therapeutic targets and won an MRC-funded scholarship in translational oncology at Imperial College London, using the latest cutting edge CRISPR/Cas9 genetic editing technology.